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DOI: 10.1039/c2md20011bWe describe here the synthesis of a library of thirty-eight squaric derivatives and the evaluation of
activity against papain-, falcipain-2- and a chloroquine-resistant strain of P. falciparum. The most
active compounds combine significant antiplasmodial activity with minimal cytotoxicity.Fig. 1 General structure of squaric acid derivatives synthesized.Introduction
Malaria is one of the most widespread infectious diseases of our
time, causing nearly 800 000 deaths each year.1 The most lethal
of the Plasmodium species that infects humans—Plasmodium
falciparum—has acquired resistance to most clinically used
antimalarials.2 Furthermore, the first cases of putative resistance
to artemisinin-based combination therapy (ACT) have been
reported. For that reason, there is an urgent need for novel
antimalarial drugs. In fact, a major challenge is to make sure that
each new generation of molecules provides antiparasitic activity
against the resistant strains.3
Following our studies on Michael acceptors as cysteine
protease inhibitors we become interested in the squaric acid
scaffold.4–8 Our interest was triggered by reports showing that
dimethyl squarate reacts efficiently with thiols to give the cor-
responding addition–elimination products,9 suggesting that
a similar process might also occur within the active site of
a cysteine protease. Moreover, since the first synthesis of squaric
acid a number of derivatives have been reported in the fields of
bioorganic and medicinal chemistry. This scaffold has already
been used with success to develop metalloenzyme inhibitors.10–13
However, the potential of this scaffold in antimalarial agents
remained to be explored. With this in mind, we developed
a library of squaramide derivatives by incorporating substituents
with different stereoelectronic properties and lipophilicities at C-
3 and C-4 (Fig. 1) in order to perform a structure–activity study
for this scaffold.
Meanwhile, in 2010, GlaxoSmithKline’s chemical library for
inhibitors of P. falciparum was made public to encourage addi-
tional drug lead identification efforts and further research intoaResearch Institute for Medicines and Pharmaceutical Sciences
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This journal is ª The Royal Society of Chemistry 2012malaria. In that library were included four compounds con-
taining a squaric moiety, with activities ranging from 62 to 878
nM against P. falciparum strain 3D7 (Fig. 2).14 Two of these
squaric acid derivatives were annotated as antagonists of sero-
tonin receptor, a drug target without obvious orthologue in the
malarial genome. More extended structure–activity data are
required to evaluate the usefulness of the squaric acid scaffold as
a starting point to develop novel antimalarials and to gain
a better understanding of their putative targets.
Results and discussion
To explore the potential of the squaric acid scaffold as an anti-
plasmodial agent we synthesized a series of compoundsFig. 2 Examples of squaric derivatives from the GSK library.
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Scheme 1 Synthesis of squaramides 4a–f, 5a–b, 6a–b and 6e–q.containing different aromatic and aliphatic amines (Scheme 1).
Commercially available squarates 1 and 2 and amines 3a–q were
used as starting materials. Squaramates 4a–f and squaramides
6g–q were obtained from dimethyl squarate 1 using one or two
equivalents of the appropriate amines. In contrast, when we used
the butyl squarate 2 and one equivalent of amines 3e–f as the
starting materials, we obtained squaramides 6e–f instead of the
corresponding squaramates 5. Squaramide 6awas obtained from
reaction of two equivalents of butyl squarate 2 and amine 3a.Table 1 Papain inhibition, falcipain-2 inhibition and antiplasmodial activity









6a Ph(p-piperidin-1-yl) 2.8  1.3












6p Ph(m-OMe) 5  1
6q Cy-C6H12 >10
E64 0.12  0.02
a ND ¼ not done.
490 | Med. Chem. Commun., 2012, 3, 489–493Interestingly, compound 6b was obtained by reflux of a mixture
of one equivalent of butyl squarate 2 and amine 3b. The same
reaction at room temperature led to compound 5b.
Compounds 4a–f, 5a–b, 6a–b and 6e–q were then screened
against papain-, falcipain-2- and the chloroquine-resistant W2
strain of P. falciparum (Table 1). Most of the compounds were
devoid of activity against P. falciparum. However, compounds
5a–b and 6a–b had low micromolar antiplasmodial activity, with
IC50 values ranging from 0.99 to 4.16 mM. Except for compounds
6a–b and 6p, all compounds were inactive against papain, the
prototype for clan CA cysteine proteases. In fact, we already
observed a similar result for squaric vinyl sulfones.6
Based on our previous results showing IC50 values of around
1 mM for squaric-Leu-azaPhe-VSPh derivatives,6 we tried to
improve the activity of these compounds, by synthesizing two
unsymmetrical squaramides. Ph(p-CMe3) and CH(CH2OH)-
(CH2Ph) were chosen as substituents due to the good activities of
compounds 5b and 6b and to test the presence of ahydroxyl group,
respectively. However, compounds 8b and 8f were devoid of
antiplasmodial activity (IC50, >10 mM) (Scheme 2).
The next step was to evaluate the potential of the squaric acid
scaffold in the design of selective falcipain inhibitors, by incor-
porating the appropriate recognition moiety at the double bond.
A series of compounds containing an aza-dipeptide recognition
moiety were synthesized in which the squaric moeity acts as
a replacement of the P1 carbonyl group. Gly, Phe and homoPhe
residueswere selected forP1.The recognitionmoietywas obtained
starting with N-BocLeu and the corresponding hydrazine.for compounds 4a–f, 5a–b and 6a–q
Falcipain-2 IC50







ND 3.13  0.35
>50 2.65  0.19
>50 4.16  0.54














0.06  0.01 1.94  0.004
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Scheme 2 Synthesis of squaramides 8b and 8f.
Scheme 3 Synthesis of aza squaric derivatives 11a–c and 13a–b.The aza-Gly compound was obtained from reaction of Boc
protected hydrazine 9a with dimetyl squarate 1. Deprotection of
the Boc group, followed by coupling with BocLeu, led to aza
squaric derivative 11a containing Gly in P1 (Scheme 3).
The aza squaric acid derivatives containing Phe and homoPhe
in P1 were synthesized starting from the corresponding BocTable 2 Papain inhibition and antiplasmodial activity for compounds 11d–h
Compounds R1 R2 R3 Aza-dip
11a Me H BocLeu BocLeu-
11b Me CH2Ph BocLeu BocLeu-
11c Me CH2CH2Ph BocLeu BocLeu-
11d Me H MuLeu MuLeu-
11e Me CH2CH2Ph MuLeu MuLeu-
11f Me CH2CH2Ph CbzLeu CbzLeu
11g Me CH2CH2Ph CbzGly CbzGly-
11h Me CH2CH2Ph CbzPhe CbzPhe-
13a Bu H BocLeu BocLeu-
13b Bu CH2CH2Ph BocLeu BocLeu-
13c Bu H MuLeu MuLeu-
13d Bu CH2CH2Ph MuLeu MuLeu-
13e Bu CH2CH2Ph CbzLeu CbzLeu
13f Bu CH2CH2Ph CbzGly CbzGly-
13g Bu CH2CH2Ph CbzPhe CbzPhe-
E64
a Insoluble, saturated solution of 1 mM was used.
This journal is ª The Royal Society of Chemistry 2012protected hydrazines 9b–c. Deprotection of the Boc group with
TFA, followed by coupling with BocLeuOH, led to amino acid
hydrazides 12b–c. Finally, coupling with the dimetyl squarate 1
led to aza squaric derivatives 11b–c in 42–47% yields (Scheme 3).
All of the proposed structures were established byNMR (1H, 13C,
COSY and HMQC), IR, and MS.and 13a–g
eptide Papain C50/mM P. falciparum W2 IC50/mM
azaGly >10 8.53  0.71
azaPhe >10 >1a
azahomoPhe >10 6.36  0.78
azaGly >10 >10
azahomoPhe >10 >10
-azahomoPhe >10 2.99  0.23
azahomoPhe >10 9.36  0.1
azahomoPhe >10 3.14  0.07
azaGly >10 >10
azahomoPhe >10 >10
azaGly >10 9.45  0.02
azahomoPhe >10 >10
-azahomoPhe >10 4.51  0.25
azahomoPhe >10 5.17  0.04
azahomoPhe >10 4.69  0.13
0.3  0.2 (nM) 1.94  0.004
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Scheme 4 Synthesis of N-Mu aza squaric derivatives 11d–e and 13c–d.
Scheme 5 Synthesis of N-Cbz aza squaric derivatives 11f–h and 13e–g.Compounds 11a–c were then screened against the W2 strain of
P. falciparum (Table 2). The results show that the recognition
moiety seems to be essential for antiplasmodial activity, as
compounds 4a–f and 6e–q, lacking the aza-dipeptidyl moiety,
were devoid of activity. In contrast, compounds 11a and 11c had
good antiplasmodial activity, with IC50 values of 9 and 6 mM,
respectively. Probably FP-2 inhibition is not the primary mode
by which derivatives 11 exert their antiplasmodial activities, since
compound 11c was not active against falcipain-2 for the tested
concentrations. In fact, all compounds were inactive against
papain.
To further explore the potential of the aza-dipeptidyl squaric
acid derivatives as antimalarials we completed our structure–
activity study by synthesizing other derivatives of compounds
11a (aza-Gly) and 11c (aza-homoPhe).
We synthesized a new series of compounds containing Cbz-
protected amino acids in P2. Gly, Leu and Phe residues in P2 were
selected in order to modulate the interaction with P2 (Scheme 4).Table 3 Cytotoxicity against NIH 3T3 and Hek 293T cells for compounds
Compounds W2 IC50/mM NIH 3T3 IC50/mM
5a 3.13  0.35 >100
5b 2.65  0.19 17.51  1.27
6a 4.16  0.54 >50
6b 0.99  0.23 >100
11a 8.53  0.71 >100
11c 6.36  0.78 >100
11f 2.99  0.23 >100
11g 9.36  0.1 >100
11h 3.14  0.07 >100
13c 9.45  0.02 >100
13e 4.51  0.25 >100
13f 5.17  0.04 >100
13g 4.69  0.13 >100
a Selectivity index toward W2 strain, which is expressed by the ratio IC50
Hek/
492 | Med. Chem. Commun., 2012, 3, 489–493Two compounds were also synthesized with a 4-morpholine-
carbonyl (Mu) protected Leu in P2 and an aza-Gly or aza-
homoPhe in P1 (Scheme 4). Commercially available methyl 1 and
butyl 2 squarates were used as starting materials.
The BocLeu butoxy squaric derivatives 13a and 13b were
synthesized using the samemethodology applied for the synthesis
of compounds 11a and 11c, respectively (Scheme 3). Compounds
11d–e and 13c–d were obtained from the corresponding BocLeu
aza squaric acid derivatives with 69–76% yields, by deprotection
of the Boc group with TFA, followed by reaction with 4-mor-
pholinecarbonyl chloride (Scheme 4). The N-Cbz protected aza
squaric acid derivatives were synthesized from the corresponding
amino acid hydrazides in 71–83% yields (Scheme 5).
Compounds 11d–h and 13a–g were then tested against papain
and against the W2 strain of P. falciparum (Table 2). Inspection
of the data in Table 2 allows the following observations:
(1) As observed before for compound 11c, azadipeptidyl
squaric derivatives did not inhibit papain at the tested
concentrations.
(2) For OMe compounds containing an aza-homoPhe or an
aza-Gly in P1 and Leu in P2, the presence of a Mu protective
group resulted in the loss of activity against P. falciparum (i.e.
compounds 11d and 11e versus their Boc-protected counterparts
11a and 11c). However, the opposite result was observed for the
inhibitor containing an aza-homoPhe in P1 and a Cbz-Leu in P2
(i.e. compound 11f). In this case, activity was increased ca. 2-fold
higher than that of its Boc-protected counterpart 11c.
(3) The order of inhibitory activity against P. falciparum for
the methoxy series depended on the nature of the P2 residue and
varied in the order Leu > Phe > Gly. However, this effect had no
major impact on activity for the butoxy series (13e vs. 13f vs.
13g).
(4) Related to the Cbz series, substitution of the OMe group
for an OBu group in the squaric moiety improved the activity ca.
2-fold only for the inhibitors containing a CbzGly amino acid
(i.e. compound 13f versus the OMe counterpart 11g).
(5) For compounds containing an aza-homoPhe or an aza-Gly
in P1 and BocLeu, the substitution of the OMe group for an OBu
group in the squaric moiety resulted in the loss of activity against
P. falciparum (i.e. compounds 13a and 13b versus their OMe
counterparts 11a and 11c).5a–b, 6a–b, 11a, 11c, 11f–h, 13c and 13e–g
Hek 293T IC50/mM SI
a log Pb
>100 >32 3.48













W2. b Estimated by the ALOGPS 2.1 algorithm.15
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(6) For compounds containing the Mu-Leu-azaGly sequence
(i.e. compounds 11d and 13c) substitution of the OMe for an
OBu group was beneficial. In fact, compound 11d was inactive
but compound 13c presented an IC50 of 9.5 mM.
The in vitro cytotoxicity of the most active compounds for
P. falciparum (compounds 5a–b, 6a–b, 11a, 11c, 11f–h, 13c and
13e–g) was evaluated using NIH 3T3 and Hek 293T cells.
Remarkably, most of the squaric derivatives were non-cytotoxic
up to 100 mM (Table 3). Only, squaramate 5b led to some
cytotoxicity when compared to the other squaric derivatives; but
even in this case, the selectivity index (SI) is ca. 5, which indicates
only modest toxicity.
Importantly, the calclogP values15 for the most active
compounds range from 1.0 to 5.7 (Table 3) suggesting that they
present appropriate cell permeability properties.
Conclusions
We have synthesized a library of 38 squaric derivatives and
evaluated activity against papain-, falcipain-2- and a chloro-
quine-resistant strain of P. falciparum.
The first series of compounds was obtained by reaction of
dimethyl or dibutyl squaramates with the appropriate amines in
moderate to good yields.
Aza-dipeptidyl squaric acid derivatives displayed good anti-
plasmodial activity against P. falciparum. The most active
compounds contained an azahomoPhe moiety at the peptidic
sequence and presented IC50 values of around 3 mM. No cysteine
protease inhibition was observed for compounds containing
a recognition moiety, suggesting that FP-2 inhibition is not the
primary mode by which derivatives 11 and 13 exert anti-
plasmodial activities.
However, the recognition moiety seems to be important for the
antiplasmodial activities of the squaric derivatives, as most of the
non-peptidic compounds were inactive against P. falciparum.
For this reason, one might speculate that the compounds are
inhibiting other proteases involved in the parasite life cycle. In
fact, in silico approaches have identified 92 putative proteases in
the P. falciparum genome.16 Further investigations are necessary
to clarify the target of these compounds.
In conclusion, several squaric acid derivatives showed signifi-
cant antiplasmodial activity against a CQ-resistant P. falciparum
strain and minimal cytotoxicity. Overall, aza dipeptide squaric
derivatives are promising lead compounds for the development
of new agents against P. falciparum malaria.This journal is ª The Royal Society of Chemistry 2012Acknowledgements
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